[1]
|
Fasano, M., Della Corte, C.M., Papaccio, F., et al. (2015) Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy. Journal of Thoracic Oncology, 10, 1133-1141.
https://doi.org/10.1097/JTO.0000000000000589
|
[2]
|
Garcia-Yuste, Matilla, J.M., Alvarez-Gago, T., et al. (2000) Prognostic Factors in Neuroendocrine Lung Tumors: A Spanish Multicenter Study. The Annals of Thoracic Surgery, 70, 258-263.
https://doi.org/10.1016/S0003-4975(00)01369-2
|
[3]
|
Akata, S., Okada, S., Maeda, J., et al. (2007) Computed Tomographic Findings of Large Cell Neuroendocrine Carcinoma of the Lung. Clinical Imaging, 31, 379-384. https://doi.org/10.1016/j.clinimag.2007.04.027
|
[4]
|
Rivera, M.P. and Mehta, A.C. (2007) Initial Diagnosis of Lung Cancer. ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition). Chest, 132, 131. https://doi.org/10.1378/chest.07-1357
|
[5]
|
Fernandez, F.G. and Battafarano, R.J. (2006) Large-Cell Neuroendocrine Carcinoma of the Lung: An Aggressive Neuroendocrine Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery, 18, 206-210.
https://doi.org/10.1053/j.semtcvs.2006.08.007
|
[6]
|
Travis, W.D., Rush, W., Flieder, D.B., et al. (1998) Survival Analysis of 200 Pulmonary Neuroendocrine Tumors with Clarification of Criteria for Atypical Carcinoid and Its Separation from Typical Carcinoid. The American Journal of Surgical Pathology, 22, 934-944. https://doi.org/10.1097/00000478-199808000-00003
|
[7]
|
Bari, M.F., Brown, H., Nicholson, A.G., et al. (2014) BAI3, CDX2 and VIL1: A Panel of Three Antibodies to Distinguish Small Cell from Large Cell Neuroendocrine Lung Carcinomas. Histopathology, 64, 547-556.
https://doi.org/10.1111/his.12278
|
[8]
|
Travis, W.D., Brambilla, E., Noguchi, M., et al. (2013) Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Socie-ty/European Respiratory Society classification. Archives of Pathology & Laboratory Medicine, 137, 668-684.
https://doi.org/10.5858/arpa.2012-0263-RA
|
[9]
|
Rekhtman, N., Pietanza, M.C., Hellmann, M.D., et al. (2016) Next-Generation Sequencing of Pulmonary Large-Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-Like and Non-Small Cell Carcino-ma-Like Subsets. Clinical Cancer Research, 22, 3618-3629. https://doi.org/10.1158/1078-0432.CCR-15-2946
|
[10]
|
Miyoshi, T., Umemura, S., Matsumura, Y., et al. (2017) Genomic Profiling of Large Cell Neuroendocrine Carcinoma of the Lung. Clinical Cancer Research, 23, 757-765. https://doi.org/10.1158/1078-0432.CCR-16-0355
|
[11]
|
LaPoint, R.J.A., Bourne, P.A., Wang, H.L., et al. (2007) Coexpression of c-Kit and bcl-2 in Small Cell Carcinoma and Large Cell Neuroendocrine Carcinoma of the Lung. Applied Im-munohistochemistry & Molecular Morphology, 15, 401-406. https://doi.org/10.1097/01.pai.0000213153.41440.7d
|
[12]
|
Eichhorn, F., Dienemann, H., Muley, T., et al. (2015) Predictors of Survival after Operation among Patients with Large Cell Neuroendocrine Car-cinoma of the Lung. The Annals of Thoracic Surgery, 99, 983-989.
https://doi.org/10.1016/j.athoracsur.2014.10.015
|
[13]
|
Iyoda, A., Hiroshima, K., Moriya, Y., et al. (2006) Prospective Study of Adjuvant Chemotherapy for Pulmonary Large Cell Neuroendocrine Carcinoma. The Annals of Thoracic Surgery, 82, 1802-1807.
https://doi.org/10.1016/j.athoracsur.2006.05.109
|
[14]
|
Le Treut, J., Sauh, M.C., Lena, H., et al. (2013) Multicentre Phase II Study of Cisplatin-Etoposide Chemotherapy for Advanced Large-Cell Neuroendocrine Lung Carcinoma: The GFPC 0302 Study. Annals of Oncology, 24, 1548-1552.
https://doi.org/10.1093/annonc/mdt009
|
[15]
|
Niho, S., Kenmotsu, H., Sekine, I., Ishii, G., et al. (2013) Combination Chemothera-py with Irinotecan and Cisplatin for Large-Cell Neuroendocrine Carcinoma of the Lung: A Multicenter Phase II Study. Journal of Tho-racic Oncology, 8, 980-984. https://doi.org/10.1097/JTO.0b013e31828f6989
|
[16]
|
Rieber, J., Schmitt, J., Warth, A., et al. (2015) Outcome and Prognostic Factors of Multimodal Therapy for Pulmonary Large-Cell Neuroendocrine Carcinomas. European Journal of Medical Research, 20, 64.
https://doi.org/10.1186/s40001-015-0158-9
|
[17]
|
Derks, J.L., Leblay, N., Thunnissen, E., et al. (2018) Molecular Subtypes of Pulmonary Large-Cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome. Clinical Cancer Research, 24, 33-42.
https://doi.org/10.1158/1078-0432.CCR-17-1921
|
[18]
|
Tsuruoka, K., Horinouchi, H., Goto, Y., et al. (2017) PD-L1 Expression in Neuroendocrine Tumors of the Lung. Lung Cancer, 108, 115-120. https://doi.org/10.1016/j.lungcan.2017.03.006
|
[19]
|
Patel, S.P., Othus, M., Chae, Y.K., et al. (2020) A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Non-Pancreatic Neuroendocrine Tumors. Clinical Cancer Research, 26, 2290-2296. https://doi.org/10.1158/1078-0432.CCR-19-3356
|